Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly earnings results on February 24, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.21, missing the consensus estimate of $-0.16 by $0.05 per share. Revenue came in at $53.7M, beating the estimate of $48.6M.
Day One Biopharmaceutical's stock moved following the earnings release. The stock currently trades at $11.12 with a market capitalization of $865.3M.